Q4-2012.
1.
GMSBiotech is pleased to announce that Mr. Milan Patel has joined as
CFO & Alan Jernigan as SVP of Sales &
Marketing. Prior to joining GMSBiotech Mr. Patel
served as Chief Financial Officer of 2020 Company, LLC- a leading
professional services firm that delivered business and technology solutions to the government, in the areas of health,
education and science,
Alan Jernigan has held previous senior level positions in prestigious companies such as One Lambda, a leader in
Transplant Diagnostics, where he was their Chief Marketing Officer.
2. GMSBiotech has secured private funding to accelerate HLA Product Launch and FDA 510(k) submission.
3.
GMSBiotech has received Letter of Certification as a Qualified Small
Business for the Small Business Capital Investment
Incentive Program from Arizona Commerce Authority.
May 2012.
gmsbiotech received a US patent (No. 8,183,360) on Population
Scale HLA-Typing and Uses Thereof on May 22, 2012.
Dr.
Krishna Jayaraman President &CEO was invited to make a presentation
and to be a panel member in the 14th Annual SBIR/STTR Conference held
in Louisville, Kentucky (May 30th-June 1st)
April 2012.
gmsbioetch received a two year R21grant from National Heart Blood
and Lung Institute for High-Throughput HLA-Typing: on Raw, Unpurified
Cord Blood Samples. Gmsbiotech will have access to archived cord blood
samples from NHLBI.
An article on this grant award appeared in Genomeweb News (May 10, 2012)
October 2011.
gmsbiotech made a poster presentation at the 37th Annual Meeting
of ASHI held in New Orleans from October 17th -21st. The title of the
presentation was ”High-Throughput HLA Typing Via Touch Rehydration of
Dried Blood On Guthrie Cards”.
September 2011.
Dr. Nutan Dighe, Senior Scientist from Bangalore Medical Services
Trust, India underwent a two- week comprehensive training in advanced
HLA Chip Technology at gmsbiotech Tucson facility.
August 2011.
gmsbiotech was awarded a Phase I SBIR grant by National Heart,
Blood and Lung Institute (NHBLI) titled "The transfusion chip: a
simple, low cost microarray for DNA-based blood typing." The
grant was awarded on Aug. 1 and is set to expire on Jan. 30, 2012.
The
grant will help gmsbiotech develop an array-based blood-screening
device that could replace existing serological techniques used in blood
banks.
June 2011. gmsbiotech
will present at Cambridge Healthtech Institute’s The Business of
Genomics:
Planning to Survive and Thrive as part of the upcoming Beyond
Sequencing
meeting, on June 20th 2011 in San Francisco.
gmsbiotech
will present at the 13th Annual NIH SBIR/STTR
Conference organized
by NIH on June 22, 2011. gmsbiotech is one of among over fifty
NIH SBIR and/or STTR Phase II awardees that will display their
scientific
findings at the meeting.
May 2011. gmsbiotech
launched beta testing of its HLA Chip technology in the ASHI-certified
Histocompatibility and Transplant Immunology laboratories of The
Methodist
Hospital, Houston TX, under the direction of Dr. Geoffrey Land. Dr.
Land is the
current President of ASHI. This beta
test program will be used to validate the technology and to obtain ASHI
Certification.
gmsbiotech
is listed in the NIH “Success Story” website. See under Genomics
USA at http://grants1.nih.gov/grants/funding/sbir_successes/sbir_successes.htm.
The companies listed in this
website have used the SBIR/STTR funding to successfully commercialize
their
products. Past inclusion in this website in the life science category
includes
companies such as Illumina and NimbleGen.
April
2011. Jennifer
Morgan, Ph.D., Senior Scientist from the New Zealand Blood Labs
completed a
comprehensive 1-week training session at GMS labs in Tucson: comprising
advanced training in HLA-Chip technology and Ricimer analysis tools.
January 2011.
gmsbiotech has expanded its R&D facility with the addition of
another 2000 sq. ft. of laboratory space.
November 10,
2010. Dr. Michael Hogan, The Chief Scientific
Officer of gmsbiotech, will be presenting a talk at the APHIA
(Asia-Pacific Histocompatibility & Immunogenetics Association)
to be held in Queenstown, New Zealand from 16-19 November 2010 titled
“Microarray-Based HLA Typing on Unpurified Samples from Blood and
Buccal Swabs”.
gmsbiotech (genomicsusa) received notification
of grant award from the
IRS for the Qualified Therapeutic Discovery Project for the
development of a microarray based HLA typing technology for
solid organ and marrow transplantations and as a diagnostic tool in the
personalized medicine applications.
Sepember 27,
2010.
gmsbiotech to present a talk and a poster at the annual meeting of the
American Society for Histocompatibility and Immunogentics (ASHI) in
Hollywood Florida (Sept 26-30th) entitled: “Microarray-Based HLA Typing
on Unpurifed DNA Samples from Blood and Buccal Swabs”. This is the
first discussion of a new gmsbiotech technology, to perform low cost
HLA
typing on raw blood, dried blood spots and from cheek swabs,in a way
that bypasses DNA purification.
August 1, 2010.
gmsbiotech launched beta testing of its HLA Chip technology in the
ASHI-certified laboratories of The New Zealand Blood Labs, Auckland NZ,
under the direction of Dr Paul Dunn. This beta test program will be
used to validate the technology, for low cost HLA typing in the context
of routine workflow in an ASHI-certified tissue typing
laboratory.
July
1, 2010.
gmsbiotech will conduct its business (DBA) in the name of gmsbiotech
(Genetics Made Simple) to reflect the simplifications inherent in its
technologies for complex, population-scale genetics.
February 23, 2010.
The US Patent and Trademark Office has awarded gmsbiotech a patent:
Hogan ME, Jayaraman K, Mitra R & Eggers RH. Population Scale
HLA
Typing and Methods Thereof. US Patent No. 7,667,026. This US patent
confirms broad protection to the design of its HLA-Chip products.
November
3,
2009.
gmsbiotech presented its HLA-Chip technology at the 35th annual
meeting of The American Society of Histocompatibility and
Immunogenetics (ASHI). This appearance was a springboard event for
gmsbiotech to obtain ASHI certification of its HLA-Chip technology.
The Company now believes this certification may be obtained in the
fourth quarter of 2010. ASHI certification will strengthen the intended
application and approval by the U.S. Food and Drug Administration for
the HLA-Chip product by 2012. The HLA-Chip product consists of gene
probes for the analysis of genetic compatibility in marrow, stem cell
& solid organ transplantation: the well-known backbone of
transplantation medicine.
August 15, 2009.
The National Institute of Allergy and Infectious Disease has awarded a
three year, Phase II SBIR Competitive Continuation grant to gmsbiotech,
to support ASHI & FDA approval of its "HLA-Chip" Product for
low cost, population-scale HLA-typing. This Phase II Continuation Grant
award is significant, in that such programs must have already completed
a successful Phase II, and the resulting product must stand ready,
during the three-year Continuation Phase, for validation and approval
by a Federal regulatory agency such as the FDA.
August 15, 2009.
The National Institute of Allergy and Infectious Disease has awarded a
two year, Phase I Advanced Technology SBIR grant to gmsbiotech, to
support development of an "AIDS-Chip" to be used for population scale
analysis of the personalized risk of HIV infection and personalized
response to AIDS therapy, based on variation in the human immune
system. This product development program is an important milestone for
GenUSA, in that it parallels the company's move into the personalized
genetic medicine of vaccines and chemical therapeutics.
July 2009. Dr. Kamala
Balakrishnan has joined the
company as an Advisor
Q3-2008. gmsbiotech received a Notice of Intent to grant the European
patent
application No. 02748133.2 titled “Methods and Devices Based Upon A
Novel Form of Nucleic Acid Duplex On A Surface”.
Q3-2008. Dr. Paul Dunn has joined the gmsbiotech team as
ASHI Director and HLA Advisor.
April 8, 2008.
The US Patent and Trademark Office has awarded to gmsbiotech,
the US
Patent 7,354,710, "Methods and devices based upon a novel form of the
nucleic acid duplex on a surface". This patent comprises an important
base for the gmsbiotech technology platform.
Q3-2006. gmsbiotech receives funding of about $3
million for 3 years effective from
September 1, 2006 for its Phase 2 grant "Population-scale HLA typing
for home land defense.
Q2-2006. gmsbiotech receives funding from QuantRx
BioMedical Corporation.
Q2-2004.
GenUSA SBIR Phase I grant "Population-scale HLA typing for home land
defense," is funded by NIAID, effective May 1, 2004. for $498,500.
Q3-2003. gmsbiotech is awarded a seed grant from Chicago
ITEC to continue its feasibility studies.
|
